Skip to content

EULAR 2025: SLE with kidney involvement (lupus nephritis)

International EULAR Current

EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update

Fanouriakis A, et al. Ann Rheum Dis. 2026;85:75–90
DOI 10.1016/j.ard.2025.09.007 · Summary checked against the source: 2026-11

Read or download the original

This 2025 update replaces the 2019 EULAR/ERA-EDTA lupus nephritis recommendations and the nephritis parts of EULAR 2023. It is titled "SLE with kidney involvement" to stress that nephritis is part of a systemic disease. 4 overarching principles and 13 recommendations.

At a glance

  1. Biopsy every patient with kidney involvement: proteinuria ≥0.5 g/24 h (UPCR ≥500 mg/g), glomerular haematuria or unexplained fall in GFR. [2b/B · p. 78]
  2. Targets: kidney function preserved by 3 months; proteinuria down ≥25% by 3 months, ≥50% by 6 months, UPCR <700 mg/g by 12 months. [p. 78]
  3. Combination therapy is now first choice, especially with poor prognostic factors: mycophenolate or low-dose IV cyclophosphamide + belimumab, mycophenolate + voclosporin or tacrolimus, or mycophenolate + obinutuzumab. [1b/A · p. 78]
  4. No distinction between proliferative (III/IV) and membranous (V) nephritis in the treatment recommendation. [p. 80]
  5. Steroids: IV methylprednisolone pulses, then oral, ≤5 mg/day by 4–6 months. [2b/C · p. 78]
  6. Continue treatment ≥3 years after response. [2b/B · p. 78]
  7. Kidney protection: RAS blockade, SGLT2 inhibitors, statins and bone protection. [5/D · p. 78]

Overarching principles

  • A. Regular monitoring for kidney involvement, expert input and timely biopsy. Watch closely in young (<30) patients, men and those with persistent serological activity.
  • B. Manage within the general SLE recommendations, including hydroxychloroquine.
  • C. Kidney involvement risks progressive CKD; manage jointly by rheumatology and nephrology.
  • D. Aim to prevent CKD progression and flares, with both immunosuppression and kidney protection.

Adapted from EULAR 2025 Table 1 [p. 77–78]

Recommendations

# Recommendation LoE/GoR
1 Kidney biopsy for persistent proteinuria ≥0.5 g/day, glomerular haematuria or unexplained GFR decline 2b/B, 2b/C
2 Targets: proteinuria ↓25% by 3 months, ↓50% by 6 months, UPCR <700 mg/g by 12 months, then as low as possible 2b/C, 2a/B, 1b/B
3 IV methylprednisolone pulses, then oral steroid tapered to ≤5 mg/day by 4–6 months; stop slowly after sustained complete response 2b/C
4 Combination therapy: (a) MMF or low-dose IV CYC + belimumab, (b) MMF + voclosporin or tacrolimus, (c) MMF + obinutuzumab. Alternatives: MMF alone or low-dose IV CYC alone 1b/A; alternatives 1a/A
5 Rapidly progressive GN: a short course (6–7 monthly pulses) of high-dose IV CYC 1a/A
6 Maintenance ≥3 years after response. Stay on MMF (± belimumab, CNI or obinutuzumab); switch CYC to MMF or azathioprine 2b/B; 1a/A
7 Sustained complete response: consider gradual withdrawal after 3 years 2a/B
8 Refractory or relapsing: switch between the drugs above and refer to experts 2b/B
9 Repeat biopsy when uncertain: response, worsening tests, or before withdrawing treatment 2b/B
10 Non-immune treatment: RAAS blockade (proteinuria or hypertension), SGLT2i (stable with proteinuria or eGFR <60), statins by CV risk, bone protection 5/D
11 Thrombotic microangiopathy (APS nephropathy, TTP-like, complement-mediated HUS): IV methylprednisolone, complement inhibitors, B-cell depletion, caplacizumab, plasma exchange, anticoagulation 4/C; 2b/C
12 Pregnancy once nephritis is inactive, after counselling and on pregnancy-compatible drugs 1b/A
13 Any kidney replacement therapy; transplant (including living donor and pre-emptive) once extrarenal disease is inactive for ≥6 months 2b/C

Adapted from EULAR 2025 Table 1 [p. 78]

Doses used in practice (from the text): IV methylprednisolone 500–2500 mg cumulative over 1–3 days, then oral prednisone 0.3–0.7 mg/kg/day for up to 4 weeks (from 25 mg/day with voclosporin), tapered to ≤5 mg/day by 4–6 months and stopped by 12–24 months if possible. Obinutuzumab was used for up to 1 year in REGENCY. [p. 78, 80]

Treatment summary

flowchart TD
    A["Active lupus nephritis<br/>(class III/IV ± V, or V)"] --> G["All: hydroxychloroquine<br/>IV MP pulses → oral GC, ≤5 mg/day by 4–6 months<br/>RAAS blockade, SGLT2i, statin, bone protection"]
    G --> C["Preferred: combination therapy<br/>MMF or low-dose IV CYC + belimumab<br/>MMF + voclosporin or tacrolimus<br/>MMF + obinutuzumab"]
    G --> S["Alternatives: MMF alone<br/>or low-dose IV CYC alone"]
    G --> H["Rapidly progressive GN:<br/>high-dose IV CYC (6–7 monthly pulses)"]
    C --> M["Response: continue ≥3 years<br/>(switch CYC to MMF or AZA)"]
    S --> M
    H --> M
    M --> W["Sustained complete response:<br/>consider gradual withdrawal"]
    C --> R["Refractory or relapsing:<br/>switch agents, refer, consider repeat biopsy"]
Built from EULAR 2025 recommendations 3–9 [p. 78]; the 2025 update has no treatment figure.

Poor prognostic factors

Suboptimal response or progression to CKD Flares
eGFR <60 at baseline Non-adherence
Previous flare Treatment for <3 years
Nephrotic-range proteinuria Incomplete response
Hypertension at baseline Ongoing extrarenal or serological activity
Male sex No hydroxychloroquine
Chronicity index >3 (with activity) Young age (<30), male
Crescents on biopsy Residual activity (NIH activity index ≥2) on repeat biopsy
Severe tubulointerstitial inflammation

Adapted from EULAR 2025 Table 2 [p. 80]

Clinical pearls

  • Biopsy threshold: proteinuria ≥0.5 g/day. ISN/RPS classes: III focal, IV diffuse proliferative, V membranous, VI advanced sclerosis.
  • Euro-Lupus low-dose CYC: 500 mg IV every 2 weeks × 6. NIH high-dose: monthly pulses.
  • Belimumab, voclosporin and obinutuzumab each beat standard care in phase 3 trials (BLISS-LN, AURORA, REGENCY).
  • SGLT2 inhibitors are now part of kidney protection in lupus nephritis.

Classes and levels of evidence

How EULAR lupus nephritis 2025 grades its recommendations. Adapted from EULAR lupus nephritis 2025 Table 1 (Oxford levels) [p. 78]. Hover over any class or level cited on this page to see what it means.

LoE Meaning Wording used
LoE 1a Systematic review of RCTs
LoE 1b Individual RCT
LoE 2a Systematic review of cohort studies
LoE 2b Individual cohort study, or a low-quality RCT
LoE 3a Systematic review of case-control studies
LoE 3b Individual case-control study
LoE 4 Case series, or poor-quality cohort or case-control studies
LoE 5 Expert opinion
Level Meaning
GoR A Based on consistent level 1 studies
GoR B Based on consistent level 2 or 3 studies, or extrapolated from level 1
GoR C Based on level 4 studies, or extrapolated from level 2 or 3
GoR D Based on level 5 evidence, or troublingly inconsistent or inconclusive studies

EULAR tags each recommendation with a level of evidence (LoE, 1a–5) and a grade of recommendation (GoR, A–D) from the Oxford Centre for Evidence-Based Medicine, written as "1b/A". Overarching principles carry no LoE. Each statement also has a level of agreement: the panel's mean score from 0 to 10.